Medicis Clears Up Acne Drug Dispute With Sandoz

Law360, New York (August 19, 2009, 2:32 PM EDT) -- Medicis Pharmaceutical Corp. has struck a deal with Sandoz Inc. in Medicis’ patent infringement suit seeking to block the launch of generic versions of acne medication Solodyn.

Medicis and the Novartis AG unit on Tuesday agreed to resolve their claims against one another in the U.S. District Court for the District of Delaware, and Sandoz agreed to be permanently enjoined from any further distribution of generic Solodyn.

The generic-drug maker can market the acne treatment, composed of minocycline HCL, in 45 milligram, 90 mg and 135...
To view the full article, register now.